Zenas BioPharma

Our recent #ZenasBio summer outing at Thompson Island was filled with fun! It was fantastic to spend time together and strengthen our connections outside of work. Special thanks to everyone who played a part in making our 2024 Summer Outing memorable!

Today we are excited to announce Orlando Oliveira as our Chief Commercial Officer! His significant global leadership delivering medicines to patients will be instrumental as the Zenas BioPharma team advances our immunology-based therapeutic candidates through the clinic. Read more, and welcome Orlando: https://lnkd.in/eR8HFGqi #autoimmune #immunology #biotech

We had a great time attending #EULAR2024 last week! Thank you to Mark Matijevic and Rachel Kirk for presenting on our clinical programs for #autoimmune disease, and to many of our other colleagues for hosting our booth. #igg4rd #SLE #wAIHA #MS

Come see the #ZenasBio team at #EULAR2024! At booth #S20, learn more about our advances in developing clinical stage #autoimmune therapies. We look forward to connecting with you! #igg4rd # #SLE #wAIHA #MS

To honor #LupusAwarenessMonth this May, our team joined with patients and their supporters in our Boston-area community and reflected on our commitment to them. We are proud to be working on a therapeutic candidate for #SLE, the most common form of #lupus, because we believe patients deserve more options. Learn more about lupus: https://lnkd.in/eHvXhPUS

We are thrilled to announce our upsized Series C financing today! With the $200 million in proceeds, we are advancing obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb to inhibit B-lineage cell activity, for patients with #autoimmunediseases. Thanks to our exceptional investors and #zenasbio team for supporting our progress as we aim to become a global leader in the development and commercialization of I&I therapies. Read the press release: https://lnkd.in/eaB8cg3D

A round of applause for this group of recently promoted team members! We’re inspired by your efforts and are looking forward to seeing your next achievements.#zenasbio #promotions 

We’re thrilled to welcome Patricia Allen to our Board of Directors! Patty’s expertise in finance coupled with her extensive leadership experience will further strengthen our board, as we continue to advance our immunology-based therapies for patients in need. Read more about it here: https://bit.ly/3ToF5Zo

During this holiday season, Zenas gave back to the Waltham, MA community by sponsoring two families in need by purchasing presents for their holiday celebrations. We wish you and your family happy holidays, and we look forward to an exciting 2024! #zenas #happyholidays

Zenas is thrilled to welcome Jen Fox as Chief Business Officer and Chief Financial Officer and Dr. Tanya Fischer as Head of R&D and Chief Medical Officer. Tanya and Jen further strengthen our deeply experienced leadership team as we advance our lead program, obexelimab, in late-stage clinical trials for multiple potential I&I indications.  #Zenas # TRUEInnovation.